0
0
Eli Lilly has announced compelling results from a late-stage clinical trial of its experimental oral weight loss pill, orforglipron, showing it helped overweight adults with type 2 diabetes lose an average of 10.5% of their body weight over 72 weeks. The trial signals a potential new oral treatment option for the millions with obesity and diabetes, moving the medication closer to regulatory approval and market availability by as early as next year.
Key Study Findings
In the largest Phase 3 trial of orforglipron, involving more than 1,600 participants with obesity or overweight combined with type 2 diabetes, the highest pill dose (36 mg daily) resulted in an average weight loss of approximately 23 pounds (10.5% of initial weight). This compares with just a 2.2% reduction in the placebo group. Two lower doses—12 mg and 6 mg daily—also demonstrated dose-dependent weight loss benefits, with 7.8% and 5.5% reductions respectively.
Importantly, the pill also significantly improved blood sugar control as measured by hemoglobin A1c, an established biomarker of diabetes management. Around 75% of patients on the highest dose reached target A1c levels of 6.5% or lower, meeting American Diabetes Association guidelines for good glycemic control. The treatment additionally lowered key cardiovascular risk factors, highlighting benefits beyond weight loss alone.
Expert Perspectives
Dr. Daniel Skovronsky, Chief Scientific Officer at Eli Lilly, described the efficacy seen in this oral therapy as “unprecedented” for patients with both obesity and diabetes—who typically find weight reduction especially challenging. He expressed optimism that earlier use of this therapy in diabetes care could slow disease progression.
However, obesity medicine experts outside the company provide a balanced view. Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Boston Medical Center, noted the pill’s over 10% average weight loss is clinically meaningful and could offer a needle-free option that increases accessibility. Yet she cautioned about higher discontinuation rates due to gastrointestinal side effects compared to injectable GLP-1 drugs, advising clinicians and patients to weigh benefits against potential adverse effects.
Dr. Howard Weintraub, clinical director of the Center for Prevention of Cardiovascular Disease at NYU Langone Health, highlighted how this pill’s positive impact on cardiovascular risk markers could translate to real-world prevention of heart attacks and strokes in a high-risk population.
Context and Comparison with Existing Therapies
Orforglipron belongs to a newer class of treatments called GLP-1 receptor agonists, which work by mimicking a gut hormone that regulates appetite and blood sugar. Injectable GLP-1 medications like Eli Lilly’s own Zepbound and Novo Nordisk’s Wegovy achieve greater average weight loss—up to around 15-20%—but require weekly injections and can cost around $1,000 per month.
The novelty of orforglipron lies in its oral tablet formulation, which could lower manufacturing costs and increase patient convenience and adherence. Unlike some oral competitors, Lilly’s pill does not impose dietary or fluid intake restrictions, potentially enhancing usability.
The 10.5% weight loss result reported in this diabetes trial is slightly lower than the 12.4% seen in a recent Lilly trial in patients with obesity but without diabetes, reflecting the well-known difficulty in managing weight loss among patients with type 2 diabetes.
Public Health Implications
With obesity and type 2 diabetes together affecting hundreds of millions globally, an effective oral weight loss medication could have significant public health impact. Improved weight and blood sugar control reduces risks for life-threatening complications including cardiovascular disease, kidney failure, and neuropathy. The easier administration of pills versus injections may broaden patient access and reduce stigma associated with injectable therapies.
At the population level, even modest sustained weight loss (5-10%) can improve health outcomes and quality of life. The approximately 10.5% average reduction seen here is clinically meaningful and offers hope for a new treatment avenue.
Potential Limitations and Considerations
Though promising, the medication is not without drawbacks. Gastrointestinal side effects such as nausea and vomiting were common, leading to about 10.6% of patients discontinuing the drug on the highest dose—higher than rates seen with injectable options. Long-term safety beyond 72 weeks remains to be fully understood.
Additionally, while orforglipron’s efficacy as a once-daily pill provides convenience, it did not match the weight loss levels achieved by some injectable GLP-1 therapies or upcoming combination drugs in development. Its role in clinical practice will depend on balancing effectiveness, safety, cost, and patient preferences.
Next Steps
Eli Lilly has stated it will submit regulatory filings globally for orforglipron by the end of 2025, seeking approvals to market the pill as a chronic weight management therapy for obesity with or without type 2 diabetes. If authorized, clinicians could have a new, oral option as soon as 2026.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
